TrialLancet (London, England)2022

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.

Lulu Bravo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.